Horizon Discovery Licenses Zinc Finger Nuclease Gene Editing Technology from Sigma-Aldrich
![](/46/pdcnewsitem/03/25/33/3z0LUl7uYp66m9e.png)
Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalised medicines, has entered into a non-exclusive license agreement with Sigma-Aldrich (Sigma) for use of their CompoZr zinc finger nuclease (ZFN) technology. The deal gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene-editing service and cell line product business units.
Horizon will immediately begin using ZFN technology as part of its unique custom cell line generation service, where both ZFN and rAAV technologies will be applied, either independently or in combination, to deliver the full spectrum of genomic modifications as efficiently and cost-effectively as possible. The offering will be marketed under Horizon’s precision gene-editing brand GENESIS.
Dr Darrin Disley, CEO of Horizon, said: “Horizon is a full service translational genomics company with its business activities encompassing the identification of the genetic drivers of disease, the creation of human disease models and their deployment in the development of targeted molecular therapeutics. I am delighted that we can now apply both ZFN and rAAV gene editing to give our customers a gold standard and technology agnostic cell-line generation service.”
Eric Rhodes, CTO of Horizon who has 15 years’ experience in ZFN and rAAV gene-editing technology, said: “Nuclease based approaches are particularly adept at achieving rapid and efficient knock-out of two or more alleles, making them a perfect complement to Horizon’s proprietary rAAV-based precision gene-editing platform. Our scientists have the expertise and now an unrivalled toolset to help guide customers towards the approach that best answers their biological question and/or suits their timescale and budget.”
Dr Paul Brooks, Global Market Segment Manager at Sigma Life Science, commented: “We are pleased that Horizon will be using their expertise to apply both gene editing technologies side by side for the benefit of the research community. The exploitation of these proven technologies is a key step in capitalizing on the wealth of genomic information now available, and in applying this to real drug discovery and development programs.”
Under the terms of the deal, Horizon will obtain ZFNs manufactured by Sigma for use in commercial development of cell based products and to provide commercial gene editing services.
Financial terms were not disclosed.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance